Abbott Receives FDA Approval for Pacemaker
核心洞察
The FDA has approved Abbott (搜索)'s AVEIR VR Mini Ventricular leadless pacemaker (搜索), the latest-generation ventricular device in the AVEIR leadless pacing platform.
The device is shortened from 38.0 to 32.5 mm, a 14% reduction versus the existing AVEIR VR Ventricular LP, while delivering industry-leading ventricular longevity.
Paired with the AVEIR AR2 Atrial LP (搜索), it forms the next evolution of the AVEIR DR (搜索) dual-chamber system, which uses i2i implant-to-implant communication for beat-to-beat synchrony.
The FDA has approved Abbott (搜索)'s AVEIR VR Mini Ventricular leadless pacemaker (搜索), the newest ventricular device in the company's AVEIR leadless pacing platform. The shorter device expands implant options within the right ventricle and broadens options for treating patients with slow heart rhythms (搜索).
The AVEIR VR Mini Ventricular LP is shortened from 38.0 to 32.5 mm, a 14% reduction compared with the existing AVEIR VR Ventricular LP, while delivering industry-leading ventricular longevity in a smaller form factor. It offers an additional option for patients who would benefit from a lower-profile device. Together with the AVEIR AR2 Atrial LP (搜索), it represents the next evolution of the AVEIR DR (搜索) system, a dual-chamber leadless pacemaker powered by Abbott (搜索)'s i2i (implant-to-implant) in-body communication technology, which enables beat-to-beat communication between two leadless pacemakers to maintain synchronous activation of the heart.
Leadless pacemakers are implanted directly into the heart through a minimally invasive catheter-based procedure and eliminate the need for cardiac leads, leaving no chest scar and no visible device. "Abbott (搜索) is advancing leadless pacing and expanding options for physicians and patients," said Randel Woodgrift, senior vice president of Abbott's cardiac rhythm management business, adding that AVEIR AR2 and AVEIR VR Mini together give physicians an optimized atrial and ventricular pairing that expands the reach of the technology to a broader patient population.